1. How I treat refractory and early relapsed acute myeloid leukemia
by Felicitas Thol, Richard F. Schlenk, Michael Heuser, and Arnold Ganser
Blood
Volume 126(3):
July 16, 2015
©2015 by American Society of Hematology

2. Algorithm for patients with early relapsed/refractory AML
Algorithm for patients with early relapsed/refractory AML. When diagnosing primary refractory AML/early relapse patients need to be evaluated for allogeneic HSCT and/or a suitable trial.
Algorithm for patients with early relapsed/refractory AML. When diagnosing primary refractory AML/early relapse patients need to be evaluated for allogeneic HSCT and/or a suitable trial. DLI, donor lymphocyte infusion; HCT-CI, Hematopoietic Cell Transplant–Comorbidity Index; LDAC, low-dose cytarabine; MEC, mitoxantrone, etoposide, cytarabine. #, § indicate that clinical trials should consider the patient’s performance status; that is, fit patients should receive more intense study medications (in most cases including chemotherapy) compared with unfit patients.
Felicitas Thol et al. Blood 2015;126:
©2015 by American Society of Hematology

3. The candidate targets in AML
The candidate targets in AML. cKIT, c-kit receptor tyrosine kinase; IDH, isocitrate dehydrogenase; ras, rat sarcoma.
The candidate targets in AML. cKIT, c-kit receptor tyrosine kinase; IDH, isocitrate dehydrogenase; ras, rat sarcoma.
Felicitas Thol et al. Blood 2015;126:
©2015 by American Society of Hematology